In Vivo is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

NicOx Eyes Continued Comeback with Second Pfizer Deal

Executive Summary

In early March, Pfizer licensed all ophthalmic rights to NicOx's nitric-oxide donating technology platform, just months after selecting and licensing a preclinical glaucoma candidate from the firms' previous, more narrow, collaboration. The moves have buoyed NicOx, which has been in the investor doghouse since 2003 when AstraZeneca chose to discontinue development of the firm's lead product, which was in Phase II trials for osteoarthritis pain.
Advertisement

Related Content

Merck's Deal Focus
Merck's Deal Focus
Tramadol Reformulations Highlight Pain Challenges and Opportunities
Tramadol Reformulations Highlight Pain Challenges and Opportunities
Tramadol Reformulations Highlight Pain Challenges and Opportunities
NicOx/AstraZeneca: Transparency vs. Partnering

Topics

Related Companies

Related Deals

Advertisement
UsernamePublicRestriction

Register

IV002728

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel